AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pfizer's Trading Volume Hits 10.66 Billion, Ranks 92nd Amid Eliquis Discount and Penicillin Shortage
Generated by AI AgentAinvest Volume Radar
Wednesday, Jul 23, 2025 6:47 pm ET1min read
Aime SummaryOn July 23, 2025, Pfizer's trading volume reached 10.66 billion, ranking 92nd in the day's stock market. Pfizer's stock price increased by 0.88%, marking two consecutive days of gains, with a total increase of 4.53% over the past two days.
Pfizer, in collaboration with
, has announced a significant initiative to offer their blockbuster blood thinner Eliquis at a 40% discount directly to patients. This move aims to bypass traditional middlemen, potentially reducing costs for patients and enhancing market access for the drug.Additionally,
has issued a warning regarding a near-term stock out of a penicillin product used to treat syphilis in pregnant women, following a recent recall. This development could impact the company's supply chain and patient access to critical medications.
Ainvest Volume Radar
Hunt down the stocks with explosive trading volume.
Latest Articles
Zillow's Stock Tumbles 3.37% Amid 495th-Ranked Trading Volume and Conflicting Institutional Insider and Analyst Signals
Jan.02 2026
Abercrombie & Fitch Stock Plunges 1.69% Amid $200M Trading Surge Ranks 483rd-Most-Traded
Jan.02 2026
Figma Shares Edge Up 0.64% on Strong Earnings, But 481st Trading Volume Rank Reflects Lingering Investor Skepticism
Jan.02 2026
Diamondback Energy Defies Energy Sector Volatility with 1.34% Surge, Ranks 466th in $210M Trading Volume
Jan.02 2026
Kinross Gold's 0.5% Rally Driven by 71.7% Volume Surge, Ranks 457th in Market Activity
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet